Amgen dons BigHat to bring AI insights to next-gen antibodiesnews2022-01-10T16:04:33+00:00January 10th, 2022|FierceBiotech|
JPM 2022: Moderna finds Carisma’s macrophage tech compelling enough for $45M cancer research dealnews2022-01-10T14:33:00+00:00January 10th, 2022|FierceBiotech|
JPM 2022: Bristol Myers buoys cell therapy interests with $3B biobucks deal with Bayer-backed Century, $70M upfront to ArsenalBionews2022-01-10T13:19:34+00:00January 10th, 2022|FierceBiotech|
BioMarin’s hemophilia A gene therapy hits goal in phase 3, teeing up FDA filing despite durability doubtsnews2022-01-10T11:59:02+00:00January 10th, 2022|FierceBiotech|
Maze Therapeutics navigates $190M financing round as it plots course to the clinicnews2022-01-10T10:55:52+00:00January 10th, 2022|FierceBiotech|
Novartis splashes cash on COVID-19 antiviral, plans FDA filing as Molecular Partners links drug to drop in hospitalization, deathnews2022-01-10T09:50:33+00:00January 10th, 2022|FierceBiotech|
JPM, Day 1: Bayer strikes a Mammoth deal, no Sunday buyouts, Pfizer delves deeper in gene editing and morenews2022-01-10T09:25:49+00:00January 10th, 2022|FierceBiotech|
JPM22, Day 1: Bayer strikes a Mammoth deal, no Sunday buyouts, Pfizer delves deeper in gene editing and morenews2022-01-10T09:25:49+00:00January 10th, 2022|FierceBiotech|
JPM 2022: Bayer taps CRISPR science from Doudna’s lab in $1B biobucks Mammoth gene therapy dealnews2022-01-08T11:42:24+00:00January 8th, 2022|FierceBiotech|
JPM 2022: Pfizer re-ups gene editing interest with $300M Beam pact, $1.35B in biobucksnews2022-01-07T17:50:42+00:00January 7th, 2022|FierceBiotech|
